二甲双胍联合孕激素用于子宫内膜肿瘤保留生育治疗:FELICIA 试验带来的启示

Adjunctive Metformin with Progestin in Fertility-Sparing Treatment of Endometrial Neoplasia: Insights from the FELICIA Trial

The FELICIA phase IIb trial found that adding metformin to progestin therapy for fertility-sparing treatment in endometrial neoplasia did not improve 3-year recurrence-free survival or remission rates, though some reproductive outcomes favored metformin. Safety was consistent with known profiles.
Genetic Variant in CUBN Gene Identified as Key Risk Factor for Metformin-Induced Vitamin B12 Deficiency

Genetic Variant in CUBN Gene Identified as Key Risk Factor for Metformin-Induced Vitamin B12 Deficiency

Researchers have identified a genetic variant in the cubilin gene (CUBN, rs1801222) that significantly increases the risk of metformin-induced vitamin B12 deficiency, with carriers of the AA genotype experiencing deficiency up to twice as fast as GG carriers. This discovery offers potential for targeted clinical monitoring in high-risk patients.
Metformin Mitigates Betamethasone-Induced Glycemic Dysregulation and Reduces Neonatal Hypoglycemia: Insights from a Randomized Clinical Trial

Metformin Mitigates Betamethasone-Induced Glycemic Dysregulation and Reduces Neonatal Hypoglycemia: Insights from a Randomized Clinical Trial

A multicenter randomized trial demonstrates that prophylactic metformin administration after antenatal betamethasone significantly improves maternal glycemic control and halves the risk of neonatal hypoglycemia in preterm infants, offering a safe intervention for a long-standing clinical challenge.
Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes

Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes

A new ex vivo study shows metformin induces ROS-driven ferroptosis in acute myeloid leukemia (AML), particularly in samples with altered lipid metabolism (IDH2, FLT3 mutations). Lipidomic remodeling, CD36-mediated fatty acid uptake, and DGAT1 activity determine sensitivity—suggesting biomarker-guided repurposing strategies and combination approaches.
Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence

Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence

Comprehensive review of metformin's role in metastatic prostate cancer with ADT highlights STAMPEDE trial's findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlines nuanced effects on metabolic syndrome and progression outcomes.